Malek Bou-Diab

Gestore di Portafoglio-Azioni presso Bellevue Asset Management AG

Finance

Profilo

Dr. Malek Bou-Diab is a Lead Portfolio Manager at Bellevue Asset Management AG.
He joined the firm in 2009.
Dr. Malek was a Portfolio Manager at Julius Baer Asset Management and was a Quant Risk Manager at Deutsche Bank in London.
He holds a Ph.D.
in Theoretical Physics from Zurich's Swiss Federal Institute of Technology (ETH) in Zurich.

Posizioni attive di Malek Bou-Diab

Società	Posizione	Inizio
Bellevue Asset Management AG Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG.	Gestore di Portafoglio-Azioni	01/01/2009

Tutte le posizioni attive di Malek Bou-Diab

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Malek Bou-Diab

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	1
Bellevue Asset Management AG Bellevue Asset Management AG Investment ManagersFinance Bellevue Asset Management AG (Bellevue AM) is the wholly-owned asset management subsidiary of Bellevue Group AG (SWX: BBN), an independent Swiss financial group. The firm is headquartered in Küsnacht, Switzerland and has additional offices in Germany, Austria and Luxembourg. Founded in 1993, Bellevue AM provides a diverse spectrum of top-tier investment solutions with a focus on global healthcare sector for private and institutional clients. They offer their flagship investment vehicle, the listed investment company BB Biotech AG.	Finance